Muscle pathology in juvenile dermatomyositis

Calore, Edenilson Eduardo; Cavaliere, Maria José; Perez, Nilda Maria

doi:10.1590/s1516-31801997000500009

Cited by 11 publications

(5 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The association of malignancy with the development of myositis has been well described in adults, but only rarely reported in children . Once remission is achieved, children appear to return to normal muscle strength and function, more frequently than adults with dermatomyositis [10][11][12] .…”

Section: Discussionmentioning

confidence: 99%

Juvenile dermatomyositis: clinical, laboratorial, histological, therapeutical and evolutive parameters of 35 patients

Sallum

Kiss

Sachetti³

et al. 2002

Arq. Neuro-Psiquiatr.

View full text Add to dashboard Cite

-This study was based on a prospective and a retrospective analysis of 35 patients who met Bohan and Peter criteria for juvenile dermatomyositis diagnosis.The mean follow-up time was three years ten months. Calcinosis was present in five (14.28 %) patients, cutaneous ulcers in four (11.42%), and systemic involvement in nine (27.71%) patients. All patients presented alterations in the serum levels of muscle enzymes, and all of them were submitted to muscle biopsy as a diagnostic procedure. Nine (25.71%) patients received corticotherapy prior to and 26 (74.28%) after the muscle biopsy. Chloroquine, methotrexate, cyclosporine, cyclophosphamide and intravenous immunoglobulin were used in patients with poor response to corticotherapy. Continuation of cutaneous manifestations was observed in 4 (11.43%) patients, laboratorial activity in 1 (2.85%), cutaneous and laboratorial activities in 3 (8.57%). Ten (28.57%) patients were out of activity, and 17 (48.57%) in remission at study end-point, on March 2002. Two (5.71%) patients died.KEY WORDS: juvenile dermatomyositis, clinical findings, muscle biopsy, treatment, evolution, outcome. Dermatomiosite juvenil: parâmetros clínicos, laboratoriais, histológicos, terapêuticos e evolutivos de 35 pacientesRESUMO -Este estudo foi baseado na análise prospectiva e retrospectiva de 35 pacientes que preencheram os critérios diagnósticos de Bohan e Peter de dermatomiosite juvenil. O tempo médio de seguimento foi de 3 anos e 10 meses. Foi observado calcinose em 5 (14,28%) pacientes, úlcera cutânea em 4 (11,42%) e envolvimento sistêmico em 9 (22,71%). Todos os pacientes apresentavam alterações nos níveis séricos das enzimas musculares e todos foram submetidos a biópsia muscular como procedimento diagnóstico. Nove (25,71%) pacientes receberam corticoterapia antes e 26 (74,28%) depois da realização da biópsia muscular. Foram utilizados cloroquina, metotrexato, ciclosporina, ciclofosfamida e imunoglobulina endovenosa em todos os pacientes que não apresentaram boa resposta ao corticóide. Houve manutenção das manifestações cutâneas em 4 (11,43%) pacientes, atividade laboratorial em 1 (2,85%), atividades cutânea e laboratorial em 3 (8,57%). Dez (28,57%) pacientes estavam fora de atividade e 17 (48,57%) em remissão por ocasião do término do estudo em março de 2002. Dois (5,71%) pacientes faleceram.

show abstract

Section: Discussionmentioning

confidence: 99%

Juvenile dermatomyositis: clinical, laboratorial, histological, therapeutical and evolutive parameters of 35 patients

Sallum

Kiss

Sachetti³

et al. 2002

Arq. Neuro-Psiquiatr.

View full text Add to dashboard Cite

show abstract

“…Intra-and inter-observer agreement in the interpretation of myopathic findings have been shown to be acceptable for experienced assessors [51]. Muscle histopathology findings may provide useful prognostic information in JDM, with muscle necrosis being associated with a relapsing course and muscle infarction with a chronic ulcerative course [52,53]. The development of a scoring system for muscle biopsy findings has been recently attempted [54].…”

Section: Electromyography and Muscle Biopsymentioning

confidence: 99%

Clinical assessment in juvenile dermatomyositis

et al. 2006

View full text Add to dashboard Cite

Juvenile dermatomyositis (JDM) is a multisystem inflammatory disease of unknown etiology that affects primarily the skin and muscles. Although the prognosis of JDM has improved considerably in the last three decades, a number of patients may develop irreversible damage due to the disease activity or its treatment. This damage may cause permanent disability and affect the quality of life of patients and their families. In the clinical management of patients with JDM, there is, therefore, the need of monitoring the level of disease activity, the accrual of organ damage, and the impact of the illness on patients' daily living. A reliable assessment of these different aspects of disease requires the availability of well-designed and standardized clinical tools. In the recent years, there has been increasing collaborative effort to devise new assessment measures and these measures have been included into disease activity and damage core sets of outcome variables that have been developed through international consensus. In addition, preliminary definitions of clinical improvement for patients with JDM and other idiopathic inflammatory myopathies have been created. In this review, the latest advances in the development of standardized instruments for the clinical assessment of JDM patients are illustrated and the recent international efforts that have led to the development of core sets of outcome measures and to preliminary definitions of improvement for JDM clinical trials are summarized.

show abstract

“…27 28 29 30 31 32 33 34 35 36 Notable infections include HIV, HTLV (PM, DM, IBM), hepatitis B (PM, DM), hepatitis C (IBM), toxoplasmosis, and borrelia (PM, DM). 37 38 39 40 41 42 Risk of IIM may also be increased after certain respiratory and gastrointestinal infections. 43 44 Drugs with a strong association with IIM include checkpoint inhibitors, D-penicillamine (PM, DM), statins (immune-mediated necrotizing myopathy), interferon, and anti–tumor necrosis factor (TNF) agents (DM).…”

Section: Myopathiesmentioning

confidence: 99%